Management of migraine in Australian general practice

Medical Journal of Australia

Volumn 187, Issue 3, 2007, Pages 142-146

  Stark, Richard J ^a,b   Valenti, Lisa ^c   Miller, Graeme C ^c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ATENOLOL; CANDESARTAN; CARBAMAZEPINE; CYPROHEPTADINE; DOSULEPIN; ENALAPRIL; GABAPENTIN; GINGER EXTRACT; HERBACEOUS AGENT; HORMONE; MAGNESIUM ASPARTATE; METHYSERGIDE; METOPROLOL; NAPROXEN; NARCOTIC ANALGESIC AGENT; NORTRIPTYLINE; PHENYTOIN; PIZOTIFEN; PROPRANOLOL; RAMIPRIL; TANACETUM PARTHENIUM EXTRACT; TIMOLOL; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; COHORT ANALYSIS; CONSENSUS; CONTROLLED STUDY; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRACTICE GUIDELINE; PREVALENCE; SHORT COURSE THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 34548173450     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01170.x     Document Type: Article

References (23)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 646-657.
2. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69.
3. Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991; 44: 1147-1157.
4. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24 Suppl 1: 9-160.
5. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001; 41: 638-645.
6. Goaclsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346: 257-270.
7. Silberstein SID, Goadsloy PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.
8. Bussone G, Diener H-C, Pfeil J, Schwalen S. Topiramate 100mg/day in migraine prevention. a pooled analysis of double-blinded randomised controlled trials. Int J Clin Pract 2005; 59: 961-968.
9. Castillo J, Munoz P, Guitera V, et al. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-196.
10. Britt H, Miller GC, Charles J, et al. General practice activity in Australia 2005-06. Canberra: Australian Institute of Health and Welfare, 2007.
11. Britt H, Miller GC, Henderson J, Bayram C. Patient-based substudies from BEACH: abstracts and research tools 1999-2006. Canberra: Australian Institute of Health and Welfare, 2007.
12. Britt H, Harris M, Driver B, et al. Reasons for encounter and diagnosed health problems: convergence between doctors and patients. Fam Pract 1992; 9: 191-194.
13. Driver B, Britt H, O'Toole B, et al. How representative are patients in general practice morbidity surveys? Fam Pract 1991; 8: 261-268.
14. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical (ATC) classification index with defined daily doses (DDDs). January 2005 ed. Oslo: WHO, 2005.
15. Silberstein SID. Practice parameter: evidence-based guidelines for migraine headache (an e idence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55: 754-762.
16. National Prescribing Service. Headache and migraine. NPS News (38),2005.
17. Lipton RB, Stewart WF, Liberman JN. Self-awareness of migraine: interpreting the labels that headache sufferers apply to their headaches. Neurology 2002; 58 (12 Suppl 7): S21 -S26.
18. Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the landmark study. Headache 2004; 44: 856-864.
19. Stewart WF, Lipton RB, Simon D. Work-related clisability~ results from the American migraine study. Cephalalgia 1996; 16: 231-238.
20. Therapeutic Guidelines Limited. Therapeutic guidelines, neurology. Version 2. Melbourne: Therapeutic Guidelines Ltd, 2002.
21. Speight TM, Avery GS. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 1972; 3: 159-203.
22. Prosser H, Almond S, Walley T Influences on GPs' decision to prescribe new drugs - the importance of who says what. Fam Pract 2003; 20: 61-68.
23. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-483.